{"id":22859,"date":"2026-05-16T01:01:28","date_gmt":"2026-05-16T05:01:28","guid":{"rendered":"https:\/\/napolilaw.com\/?page_id=22859"},"modified":"2026-05-16T01:02:01","modified_gmt":"2026-05-16T05:02:01","slug":"ozempic-lawsuit-lawyer-in-new-york-city","status":"publish","type":"page","link":"https:\/\/www.napolilaw.com\/es\/ozempic-lawsuit-lawyer-in-new-york-city\/","title":{"rendered":"Ozempic Lawsuit Lawyer in New York City"},"content":{"rendered":"

Ozempic Lawsuit Lawyer in New York City<\/span><\/h1>\n

If you took Ozempic or another GLP-1 medication and experienced sudden vision loss, you may have the right to pursue compensation. Napoli Shkolnik is currently reviewing Ozempic NAION claims on behalf of individuals across New York City, and we are prepared to help you understand what our <\/span>New York pharmaceutical litigation lawyer<\/b> could do for your situation.<\/span><\/p>\n

Our firm has recovered over $20 billion for clients<\/b> in personal injury and mass tort litigation.\u00a0<\/span><\/p>\n

Litigation over Ozempic and related GLP-1 drugs is active and growing at the national level. An Ozempic lawsuit lawyer in New York City from our team can review your medical history, explain where the MDL stands, and help you determine whether you may have a claim worth pursuing.<\/span><\/p>\n

How the Ozempic MDL Works<\/span><\/h2>\n

As a <\/span>Abogado de lesiones personales de Nueva York<\/span><\/a> team with deep national mass tort experience, we understand how MDL proceedings work and how to position individual claims within that structure.\u00a0<\/span><\/p>\n

In an MDL, cases are consolidated for pretrial purposes, including discovery and procedural motions. Individual cases retain their own merit, but benefit from the shared resources and strategy of the broader litigation.<\/span><\/p>\n

The MDL process also typically includes bellwether trials, which are early test cases tried before a broader settlement is reached. The outcome of those trials often shapes the settlement amounts available to other claimants. Our attorneys follow these proceedings closely on behalf of every client we represent.<\/span><\/p>\n

Ozempic and NAION: What the Research Shows<\/span><\/h2>\n

Non-Arteritic Anterior Ischemic Optic Neuropathy, or NAION, is a serious eye condition that occurs when blood flow to the optic nerve is suddenly reduced. The result can be permanent, partial, or complete vision loss in one or both eyes. There is no established treatment that reverses the damage once it occurs.<\/span><\/p>\n

Studies have identified a potential association between GLP-1 receptor agonist drugs like Ozempic and an elevated risk of NAION. Plaintiffs in the current litigation allege that Novo Nordisk, the manufacturer of Ozempic, knew or should have known about this risk and failed to adequately warn patients and prescribing physicians.\u00a0<\/span><\/p>\n

If you were diagnosed with NAION after taking Ozempic, you may have grounds for a claim. Contact our Ozempic lawsuit lawyers to learn your legal options.<\/span><\/p>\n

Who May Be Eligible to File an Ozempic Lawsuit?<\/span><\/h2>\n

Eligibility for the Ozempic litigation depends on the specific facts of your situation. Our attorneys review each case individually, but certain circumstances commonly support a viable claim.<\/span><\/p>\n

You may be eligible to file an Ozempic lawsuit if:<\/span><\/p>\n

    \n
  • You took Ozempic or another GLP-1 receptor agonist drug<\/span><\/li>\n
  • You were diagnosed with NAION during or after your use of the drug<\/span><\/li>\n
  • You were not adequately warned of the potential risk of vision loss before starting treatment<\/span><\/li>\n
  • Your NAION diagnosis required medical intervention or resulted in lasting vision impairment<\/span><\/li>\n
  • You can provide medical records documenting both your drug use and your diagnosis<\/span><\/li>\n<\/ul>\n

    If you are unsure whether your situation qualifies, a consultation with our team can help you get clarity. We review cases at no cost and with no obligation.<\/span><\/p>\n

    Legal Theories in Ozempic Litigation<\/span><\/h2>\n

    Pharmaceutical injury cases can be pursued under more than one legal theory. Our attorneys evaluate all available options when reviewing an Ozempic claim.<\/span><\/p>\n

    The most common theories in dangerous drug litigation include:<\/span><\/p>\n

      \n
    • Negligent failure to warn:<\/b> The manufacturer failed to adequately disclose known risks, including the potential link between Ozempic and NAION, to patients and prescribers<\/span><\/li>\n
    • Defective product:<\/b> The drug itself caused harm, and the manufacturer may be held strictly liable for those damages, regardless of whether a warning was provided<\/span><\/li>\n
    • Public nuisance:<\/b> When a dangerous product injures a large number of people, this theory may apply to address the broader harm caused by widespread distribution<\/span><\/li>\n<\/ul>\n

      The appropriate theory, or combination of theories, for your situation depends on the facts of your individual case. Our team will assess which approach gives your claim the strongest foundation.<\/span><\/p>\n

      Ozempic Lawsuit Lawyers in New York City at Napoli Shkolnik<\/span><\/h2>\n

      Napoli Shkolnik has built its national reputation on exactly this kind of litigation: large-scale, science-driven cases against major pharmaceutical manufacturers. Our mass tort practice has included representation of individuals, municipalities, and state governments in some of the most significant litigation of the past two decades.<\/span><\/p>\n

      Our in-house medical review team, made up of physicians, registered nurses, and former claims adjusters, evaluates the medical evidence in every case we accept. Connecting a vision loss diagnosis to a specific drug requires careful review of the clinical record, and we have the resources to do that work thoroughly.<\/span><\/p>\n

      We have served tens of thousands of clients over more than 150 years of combined legal experience. Our multilingual staff, including native Spanish, Korean, and Russian speakers, allows us to serve New York City’s diverse communities. Every client receives the same level of attention, regardless of the size of the claim.<\/span><\/p>\n

      What Compensation May Be Available?<\/span><\/h2>\n

      Individuals pursuing Ozempic NAION claims have sought compensation for a broad range of losses. The damages available in your case will depend on the severity of your vision loss and the impact it has had on your life and livelihood.<\/span><\/p>\n

      Compensation in pharmaceutical injury cases may include medical expenses related to diagnosis and treatment, lost income if your vision impairment affected your ability to work, pain and suffering, emotional distress, and reduced quality of life. In cases where a manufacturer’s conduct is found to be particularly egregious, courts may also consider punitive damages.<\/span><\/p>\n

      Our attorneys work to identify and pursue every category of compensation that may apply to your individual situation.<\/span><\/p>\n

      Contact an Ozempic Attorney in New York City<\/span><\/h2>\n

      If you took Ozempic and were later diagnosed with NAION, Napoli Shkolnik is ready to review your case. <\/span>Contact us today to schedule a free consultation with an Ozempic lawsuit lawyer in New York City.<\/b><\/p>\n

      We bring national resources, an in-house medical review team, and a documented record of results to every pharmaceutical case we handle. Whether your claim proceeds as part of the MDL or on another path, you will receive the same preparation and attention we bring to every client we serve.<\/span><\/p>","protected":false},"excerpt":{"rendered":"","protected":false},"author":52,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-22859","page","type-page","status-publish","hentry"],"acf":[],"page_builder_type":"gutenberg","gutenberg_data":[],"_links":{"self":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/pages\/22859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/users\/52"}],"replies":[{"embeddable":true,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/comments?post=22859"}],"version-history":[{"count":1,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/pages\/22859\/revisions"}],"predecessor-version":[{"id":22860,"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/pages\/22859\/revisions\/22860"}],"wp:attachment":[{"href":"https:\/\/www.napolilaw.com\/es\/wp-json\/wp\/v2\/media?parent=22859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}